The Evolution Of Biotechnology And Its Impact On Health Care

Abstract

For more than three decades the field of biotechnology has had an extraordinary impact on science, health care, law, the regulatory environment, and business. During this time more than 260 novel biotechnology products were approved for over 230 indications. Global sales of these products exceeded $175 billion in 2013 and have helped sustain a vibrant life sciences sector that includes more than 4,600 biotech companies worldwide. In this article we examine the evolution of biotechnology during the past three decades and the profound impact that it has had on health care through four interrelated and interdependent tracks: innovations in science, government activity, business development, and patient care. The future impact of biotechnology is promising, as long as the public and private sectors continue to foster policies and provide funds that lead to scientific breakthroughs; governments continue to offer incentives for private-sector biotech innovation; industry develops business models for cost-effective research and development; and all stakeholders establish policies to ensure that the therapeutic advances that mitigate or cure medical conditions that currently have inadequate or no available therapies are accessible to the public at a reasonable cost.

Producción de proteínas recombinantes a partir de animales transgénicos: Sistemas y aplicaciones

“…Además, el desarrollo de procesos a escala industrial ha representado un gran ingreso a las compañías farmacéuticas. Se estima que en el 2013 se obtuvieron ganancias por más de 175 000 millones de dólares por la venta de productos recombinantes [4]. Una de las razones de este gran auge está ligada a la variedad de disciplinas que abarca la Biotecnología, tales como Bioinformática, Ingeniería, Nanotecnología, Biología Molecular, Bioquímica, entre otras [5].…”

Pharma Success in Product Development—Does Biotechnology Change the Paradigm in Product Development and Attrition

“…These favorable impacts of biotechnology on new product approvals has evolved only in the past 32 years since the approval of the first product considered to be biotech in origin, recombinant human insulin in 1982, up to today, 2015. Evolution of the biotechnology industry (both science and business) involved simultaneously, and in an integrated nature, scientific advances with novel technologies, generally favorable government regulations, novel business practices, and the new products expanding and advancing patient care, all of which were recently reviewed in Health Affairs in February 2015 (8).…”

“…Plus over 130 added indications are approved by FDA as well over the same timeframes. The breadth of the health care impact of biotech products is equally impressive, based on number of indications in 16 medical disciplines listed: cardiology-14, dermatology-17, endocrinology-24, gastroenterology-7, gynecology-12, hematology-11, infectious disease-26, nephrology-3, neurology-11, oncology-59, ophthalmology-10, pediatrics-50+, pulmonary-4, rheumatology-13, surgery-4, urology-5, and others-23 (8,10). Many indications revolutionized the care of patients with novel mechanisms of actions to substantially arrest disease progression or even create cures for the first time in many diseases, e.g., interferons in multiple sclerosis; monoclonal antibodies in breast cancer, respiratory syncytial virus infection, and psoriasis; fusion proteins for macular degeneration and rheumatoid arthritis; enzymes for Gaucher's disease and Fabry's disease; and proteins for anemia and childhood growth deficits.…”

“…Pharma companies commonly market a very large number of the biotech products: the top 10 pharma companies market over 160 biotech products. The top 5 companies in 2014 were Roche-30.1 billion USD in biotech sales (21 bio-products), Sanofi-13.9 billion USD (23 bio-products), Novo Nordisk-14.2 billion USD (11 bio-products), AbbVie-13.9 billion USD (7 bio-products), and Pfizer-13.3 billion USD (14 bio-products) (8). Because of the novelty of the biotech molecules and their substantial impact on disease progression, biotech products have been generally well received by payers in health care systems with routine formulary approvals, even with the premium pricing carried by these products.…”

Cover Picture: Towards a Sustainable Manufacture of Hierarchical Zeolites (ChemSusChem 3/2014)

“…Im Jahr 2013 ergaben sich aus Biologika Umsätze von mehr als 175 Mrd. US‐Dollar (USD) 1,2. Bereits 47 % aller Blockbuster — Medikamente mit mehr als 1 Mrd.…”